EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder

Richard B Lipton, Verena Ramirez Campos, Zipi Roth-Ben Arie, Maja Galic, Dimos Mitsikostas, Cristina Tassorelli, Lex Denysenko, Joshua M Cohen

JAMA Neurology · 01.06.2025 · 82 (6) · 560

DOI: 10.1001/jamaneurol.2025.0806 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Neurology, erschienen am 01.06.2025. Verfasst von Richard B Lipton und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Neurology, Psychiatry and Behavioral Sciences, and the Montefiore Headache Center, Albert Einstein College of Medicine, New York, New …. Hauptthemen laut MEDLINE: Migraine Disorders, Major Depressive Disorder, Antibodies, Monoclonal. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Migraine and major depressive disorder are frequently comorbid; however, evidence evaluating the efficacy of preventive migraine therapy in patients with both diseases is limited.

Objective

To evaluate the efficacy and safety of fremanezumab in adults with migraine and comorbid major depressive disorder. Design, Setting, and Participants The UNITE study was a double-blind, placebo-controlled, parallel-group, randomized clinical trial consisting of a 4-week screening period, 12-week double-blind period, and 12-week open-label extension (OLE), conducted between July 9, 2020, and August 31, 2022. The trial was conducted at 55 centers across 12 countries. Eligible patients were adults with episodic migraine (EM) or chronic migraine (CM), history of major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) criteria for 12 or more months before screening, and active symptoms of depression (9-item Patient Health Questionnaire score of 10 or more) at screening.

Interventions

Patients were randomized 1:1 to receive monthly fremanezumab (225 mg) or matched placebo. All patients in the OLE received quarterly fremanezumab (675 mg). Main Outcomes and Measures The primary end point was the mean change from baseline in monthly migraine days during the 12-week double-blind period.

Results

Of the 540 patients screened for the study, 353 patients (mean [SD] age, 42.9 [12.3] years; 310 female [88%]; EM, 48%; CM, 52%) were eligible and randomized to receive fremanezumab (n = 175) or placebo (n = 178). Mean (SE) change from baseline in monthly migraine days during the 12-week double-blind period was −5.1 (0.50; 95% CI, −6.09 to −4.13) for fremanezumab and −2.9 (0.49; 95% CI, −3.89 to −1.96) for placebo ( P <.001). Mean (SE) change from baseline in the Hamilton Depression Rating Scale–17 Items score at week 8 was −6.0 (0.55; 95% CI, −7.10 to −4.95) for fremanezumab and −4.6 (0.54; 95% CI, −5.66 to −3.55) for placebo (least squares mean [SE] difference: −1.4 [0.61]; 95% CI, −2.61 to −0.22; P = .02). Adverse events were consistent with other fremanezumab trials. Results were maintained throughout the OLE. Conclusions and Relevance Treatment with fremanezumab compared with placebo resulted in significant reductions in monthly migraine days and depressive symptoms. No new safety concerns were observed. To the authors’ knowledge, this was the first placebo-controlled, randomized clinical trial, specifically designed to assess patients with migraine and comorbid depressive disorder, to demonstrate significant improvements in migraine and depressive symptoms with a single pharmacological intervention. Trial Registration ClinicalTrials.gov Identifier: NCT04041284

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersMajor Depressive DisorderAntibodies, MonoclonalHumansFemaleMaleDouble-Blind MethodAdultMiddle AgedTreatment OutcomeComorbidity

Substanzen

fremanezumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Departments of Neurology, Psychiatry and Behavioral Sciences, and the Montefiore Headache Center, Albert Einstein College of Medicine, New York, New York.
  • Teva Branded Pharmaceutical Products R&D Inc, West Chester, Pennsylvania.
  • Teva Pharmaceutical Industries Ltd, Tel Aviv, Israel.
  • Teva-Pharma, Produtos Farmacêuticos, Lda, Porto Salvo, Portugal.
  • Department of First Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Zitieren

APA

Lipton, R. B., Ramirez Campos, V., Roth-Ben Arie, Z., Galic, M., Mitsikostas, D., Tassorelli, C., Denysenko, L., & Cohen, J. M. (2025). Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder. JAMA Neurology, 82(6), 560. https://doi.org/10.1001/jamaneurol.2025.0806

Vancouver

Lipton RB, Ramirez Campos V, Roth-Ben Arie Z, Galic M, Mitsikostas D, Tassorelli C, et al. Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder. JAMA Neurology. 2025;82(6):560. doi:10.1001/jamaneurol.2025.0806

BibTeX
@article{Lipton2025,
  author = {Lipton, Richard B and Ramirez Campos, Verena and Roth-Ben Arie, Zipi and Galic, Maja and Mitsikostas, Dimos and Tassorelli, Cristina and Denysenko, Lex and Cohen, Joshua M},
  title = {Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder},
  journal = {JAMA Neurology},
  year = {2025},
  volume = {82},
  number = {6},
  pages = {560},
  doi = {10.1001/jamaneurol.2025.0806}
}
Kostenlos starten →